Syndax Pharmaceuticals Inc (SNDX) Financial Statements (2025 and earlier)

Company Profile

Business Address 730 THIRD AVENUE
NEW YORK, NY 10017
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments572,884570,698475,802439,936293,06559,775
Cash and cash equivalent154,083295,39474,356221,965115,24324,609
Short-term investments418,801275,304401,446217,971177,82235,166
Restricted cash and investments 217217115   
Receivables10,2361,227583429175116
Inventory, net of allowances, customer advances and progress billings366     
Inventory366     
Prepaid expense1,9951,0338861,022802727
Deposits current assets10,0296,8858,5956,8944,6831,297
Other undisclosed current assets7,3308163,805115139416
Total current assets:603,057580,876489,786448,396298,86462,331
Noncurrent Assets
Operating lease, right-of-use asset2,0221,4871,039983290716
Property, plant and equipment  820278192281
Long-term investments and receivables119,52029,8295,469   
Long-term investments119,52029,8295,469   
Restricted cash and investments217217115   
Other noncurrent assets  463807 1,267197
Total noncurrent assets:121,75932,0047,4501,2611,7491,194
TOTAL ASSETS:724,816612,880497,236449,657300,61363,525
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities26,90923,47112,25112,3757,6229,647
Employee-related liabilities4,3423,2132,800
Accounts payable11,6269,9614,3505,6693,5086,178
Accrued liabilities15,28313,5107,9012,364901669
Deferred revenue     1,5171,517
Debt     2,285478
Derivative instruments and hedges, liabilities    187  
Other undisclosed current liabilities76,64034,62516,8148,1217,4486,726
Total current liabilities:103,54958,09629,06520,68318,87218,368
Noncurrent Liabilities
Long-term debt and lease obligation 331,565  20,60617,935419
Long-term debt, excluding current maturities 331,565  19,89517,834 
Liabilities, other than long-term debt 1,578578709 11,61813,138
Deferred revenue     11,61713,133
Other liabilities     15
Operating lease, liability 1,578578709711101419
Other undisclosed noncurrent liabilities 1013(711)  
Total noncurrent liabilities:333,14358872220,60629,55313,557
Total liabilities:436,69258,68429,78741,28948,42531,925
Equity
Equity, attributable to parent288,124554,196467,449408,368252,18831,600
Common stock987653
Additional paid in capital1,509,1101,456,3701,161,288952,019820,815527,067
Accumulated other comprehensive income (loss)163218(806)45(4) 
Accumulated deficit(1,221,158)(902,400)(693,040)(543,702)(568,628)(495,470)
Total equity:288,124554,196467,449408,368252,18831,600
TOTAL LIABILITIES AND EQUITY:724,816612,880497,236449,657300,61363,525

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues23,680  139,7091,5171,517
Gross profit:23,680  139,7091,5171,517
Operating expenses(363,352)(229,954)(151,757)(113,489)(72,940)(59,056)
Operating income (loss):(339,672)(229,954)(151,757)26,220(71,423)(57,539)
Nonoperating income (expense)20,91420,5942,419(1,294)(1,735)1,492
Investment income, nonoperating26,09021,1635,872403841 
Other nonoperating income (expense)(247)(361)(316)202(219)(79)
Interest and debt expense(4,929)(208)(3,137)(1,899)(2,357) 
Income (loss) from continuing operations:(323,687)(209,568)(152,475)23,027(75,515)(56,047)
Income (loss) before gain (loss) on sale of properties:23,027(75,515)(56,047)
Other undisclosed net income4,9292083,1371,8992,357 
Net income (loss):(318,758)(209,360)(149,338)24,926(73,158)(56,047)
Other undisclosed net income attributable to parent      
Net income (loss) attributable to parent:(318,758)(209,360)(149,338)24,926(73,158)(56,047)
Other undisclosed net loss available to common stockholders, basic     (3,906) 
Net income (loss) available to common stockholders, diluted:(318,758)(209,360)(149,338)24,926(77,064)(56,047)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(318,758)(209,360)(149,338)24,926(73,158)(56,047)
Comprehensive income (loss):(318,758)(209,360)(149,338)24,926(73,158)(56,047)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(55)1,024(851)49(4)25
Comprehensive income (loss), net of tax, attributable to parent:(318,813)(208,336)(150,189)24,975(73,162)(56,022)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: